Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 88
Filtrer
1.
Animal ; 17(11): 100898, 2023 Nov.
Article de Anglais | MEDLINE | ID: mdl-37558583

RÉSUMÉ

Increased ruminal butyrate production is considered to have a positive impact on rumen epithelium growth and function. However, excessive ruminal butyrate production may affect the rumen negatively, particularly when the rumen is already challenged with low pH. The aim of this study was to determine the effect of the inclusion of concentrates in the diet and sodium butyrate (SB) supplementation on ruminal epithelium growth and function in growing rams. Forty-two rams (27.8 ± 7.3 kg; 9-14 months of age) were allocated into six treatments and fed a diet with low (22.5% of diet DM; LOW) or high (60% of diet DM; HIGH) inclusion of concentrates in combination with no (SB0), 1.6% (SB1.6) or 3.2% (SB3.2) of diet DM inclusion of SB. There was no impact of the investigated factors on papilla dimensions and mucosa surface area, either in the atrium ruminis or ventral rumen (P ≥ 0.11). Stratum corneum thickness was higher for HIGH compared to LOW treatments (P ≤ 0.04), independently of the location in the rumen. In the atrium ruminis, the epithelium and living strata thickness quadratically increased due to SB supplementation for LOW treatments but quadratically decreased for HIGH treatments (concentrate inclusion × butyrate supplementation interaction; P ≤ 0.03); conversely, in the ventral sac of the rumen, a thicker epithelium was observed due to both increased concentrate inclusion in the diet and SB supplementation (P < 0.01) but living strata thickness was increased only by SB supplementation (linear effect; P < 0.01). The epithelium damage index in the ventral sac of the rumen was higher for LOW compared to HIGH treatments (P = 0.02). Increased inclusion of concentrates in the diet increased mRNA expression of monocarboxylate transporter 1 in both the epithelium of the atrium ruminis and ventral rumen, occludin in the epithelium of the atrium ruminis and downregulated in adenoma in the epithelium of the ventral rumen (P ≤ 0.02). Protein expression of claudin-4 in the epithelium of the ventral rumen was the highest for the HIGH/SB1.6 and HIGH/SB3.2 treatments (significant effect of interaction between main effects; P < 0.01). Under the conditions of the current study, increased intake of concentrates had mostly positive effects on ruminal epithelium in growing rams, and the same was observed for the effect of SB supplementation. However, the effect of SB supplementation was at least partially affected by the inclusion of concentrates in the diet.


Sujet(s)
Aliment pour animaux , Rumen , Ovis , Animaux , Mâle , Acide butyrique , Rumen/métabolisme , Aliment pour animaux/analyse , Épithélium/métabolisme , Ovis aries , Régime alimentaire/médecine vétérinaire , Compléments alimentaires , Fermentation , Acides gras volatils/métabolisme
3.
Indian J Dermatol ; 66(2): 187-190, 2021.
Article de Anglais | MEDLINE | ID: mdl-34188276

RÉSUMÉ

Leukemia cutis (LC) is a term describing skin lesions caused by cutaneous infiltration by hematological malignancies (myeloid or lymphoid). To our knowledge, there are no published reports on dermoscopic presentation of LC. The aim of the study was to analyze dermoscopic pattern in series of 5 patients with the diagnosis of LC.

4.
Domest Anim Endocrinol ; 73: 106472, 2020 10.
Article de Anglais | MEDLINE | ID: mdl-32265081

RÉSUMÉ

Increased adipose mass can cause insulin resistance and type 2 diabetes mellitus. This phenomenon is related to adipocyte-secreted signaling molecules that affect glucose balance, such as fatty acids, adiponectin, leptin, interleukin-6, tumor necrosis factor-α, and resistin. Among these hormones, leptin and resistin play important roles in regulating weight and glucose metabolism. Leptin and resistin work in both similar and opposite ways, and they interact with each other. Circulating concentrations of leptin and resistin are elevated in models of obesity and rodents fed a high-fat diet. In addition, leptin and resistin are similarly regulated by nutritional status: they are reduced by fasting and increased by feeding. This effect is mediated partially through insulin receptors and glucose transporters. Our latest data provided the first indication that in sheep, intravenous infusion of resistin increases the mean circulating concentrations of leptin and decreases luteinizing hormone in a dose-dependent manner during both the long-day (LD) and short-day seasons. Furthermore, exogenous resistin increased suppressor of cytokine signaling (SOCS)-3 mRNA expression only during the LD season, when the leptin resistance/insensitivity phenomenon was observed in the arcuate nucleus, preoptic area, and anterior pituitary. We concluded that one factor contributing to central leptin resistance is autosuppression, via which leptin and resistin stimulate the expression of SOCS-3, which inhibits leptin signaling. The increased expression of SOCS-3 in response to leptin and resistin may be a pivotal cause of leptin resistance/insensitivity, a pathological situation in obese individuals and a physiological occurrence in sheep during the LD season.


Sujet(s)
Métabolisme énergétique/physiologie , Leptine/métabolisme , Reproduction/physiologie , Résistine/métabolisme , Animaux , Régulation de l'expression des gènes/physiologie
5.
Clin Exp Dermatol ; 45(2): 165-171, 2020 Mar.
Article de Anglais | MEDLINE | ID: mdl-31323143

RÉSUMÉ

BACKGROUND: The molecular pathogenesis of basal cell carcinoma (BCC) is still not precisely described and is the subject of ongoing studies. The role of signal transducers and activators of transcription (STATs) in human epithelial carcinogenesis has been poorly investigated, but in the era of studies on inhibitors targeting STAT proteins this topic seems worth exploring. Increased expression of STAT3 in human nonmelanoma skin cancer (NMSC) has been confirmed in a few studies, but to our knowledge, expression of STAT5A, STAT5B and STAT6 in BCC has not been previously evaluated. AIM: To measure expression of STAT3, STAT5A, STAT5B and STAT6 expression in different histopathological subtypes of human BCC and its correlation with selected clinical variables. METHODS: Immunohistochemistry was used to assess 60 BCC tumour specimens [20 superficial (s)BCCs, 20 nodular (n)BCCs and 20 infiltrative (i)BCCs] and to compare with specimens of healthy skin. There was no significant difference in age or sex between the three groups of patients with BCC. As many tumours showed heterogeneity of staining, the H-score system was applied to calculate the intensity of immunoexpression. RESULTS: Expression of STAT3, STAT5A, STAT5B and STAT6 was observed in all histopathological subtypes of BCC, and was stronger than the expression within the adjacent epidermis and also stronger than the expression within the epidermis in the healthy control group. Statistical analysis revealed no significant differences in mean H-scores calculated for sBCCs, nBCCs and iBCCs. There were no statistically significant associations between STAT3, STAT5A, STAT5B and STAT6 expression and patient sex/age, and tumour size/site. CONCLUSION: Our results confirm a possible role of STATs in the pathogenesis of BCC and should encourage future investigations on the possible therapeutic implications of this finding.


Sujet(s)
Carcinome basocellulaire/métabolisme , Facteurs de transcription STAT/métabolisme , Tumeurs cutanées/métabolisme , Humains , Immunohistochimie , Facteur de transcription STAT-3/métabolisme , Facteur de transcription STAT-5/métabolisme , Facteur de transcription STAT-6/métabolisme , Transduction du signal/physiologie , Statistique non paramétrique , Protéines suppresseurs de tumeurs/métabolisme
8.
Ann Oncol ; 29(1): 200-208, 2018 01 01.
Article de Anglais | MEDLINE | ID: mdl-29186353

RÉSUMÉ

Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods: Clinically annotated, resected stage I-III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is >1% for most of the ∼150 (13 genes) mutations covered in the multiplex test. Results: Multiplex testing has been carried out in 2063 (76.2%) of the 2709 Lungscape cases (median follow-up 4.8 years). FFPE samples mostly date from 2005 to 2008, yet recently extracted DNA quality and quantity was generally good. Average DNA yield/case was 2.63 µg; 38 cases (1.4%) failed QC and were excluded from study; 95.1% of included cases allowed the complete panel of mutations to be tested. Most common were KRAS, MET, EGFR and PIK3CA mutations with overall prevalence of 23.0%, 6.8%, 5.4% and 4.9%, respectively. KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas. MET mutation prevalence did not differ between histology groups. EGFR mutations were found predominantly in never smokers; KRAS in current/former smokers. For all the above mutations, there was no difference in outcome between mutated and non-mutated cases. Conclusion: Archival FFPE NSCLC material is adequate for multiplex mutation analysis. In this large, predominantly European, clinically annotated stage I-III NSCLC cohort, none of the mutations characterized showed prognostic significance.


Sujet(s)
Carcinome pulmonaire non à petites cellules/génétique , Tumeurs du poumon/génétique , Mutation , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Kinase du lymphome anaplasique/biosynthèse , Kinase du lymphome anaplasique/génétique , Carcinome pulmonaire non à petites cellules/épidémiologie , Carcinome pulmonaire non à petites cellules/anatomopathologie , Analyse de mutations d'ADN/méthodes , Femelle , Humains , Tumeurs du poumon/épidémiologie , Tumeurs du poumon/anatomopathologie , Mâle , Adulte d'âge moyen , Réaction de polymérisation en chaine multiplex/méthodes , Stadification tumorale , Prévalence , Survie sans progression , Protéines proto-oncogènes c-met/biosynthèse , Protéines proto-oncogènes c-met/génétique , Fumer/génétique , Jeune adulte
9.
Br J Dermatol ; 177(5): 1376-1384, 2017 Nov.
Article de Anglais | MEDLINE | ID: mdl-28734009

RÉSUMÉ

BACKGROUND: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. OBJECTIVES: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. METHODS: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. RESULTS: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. CONCLUSIONS: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.


Sujet(s)
Marqueurs biologiques tumoraux/génétique , Mélanome/génétique , Mutation/génétique , Protéines proto-oncogènes c-kit/génétique , Tumeurs de la vulve/génétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Survie sans rechute , Femelle , Humains , Estimation de Kaplan-Meier , Mélanome/mortalité , Adulte d'âge moyen , Pronostic , Protéines proto-oncogènes B-raf/génétique , Protéines proto-oncogènes c-kit/métabolisme , Études rétrospectives , Tumeurs de la vulve/mortalité , Jeune adulte
10.
Pol J Pathol ; 67(2): 130-5, 2016 Jun.
Article de Anglais | MEDLINE | ID: mdl-27543867

RÉSUMÉ

Olfactory neuroblastoma (ONB) is a rare neoplasm of the sinonasal area with neuroendocrine differentiation. ISL-1, TTF-1 and PAX5 are transcription factors that are frequently upregulated in tumors showing neuroendocrine differentiation. The aim of our study was to evaluate these markers in a group of ONBs. We included 11 ONBs from 4 large university hospitals. Immunohistochemical expression of TTF-1, PAX5 and ISL-1 was evaluated. TTF-1, ISL-1 and PAX5 were expressed in 3/11 cases (27.27%, h-score: 3-45), 7/11 cases (63.64%, h-score: 23-200), and in 3/11 cases (27.77%, h-score 3-85), respectively. The patient with the strongest PAX5 reactivity exhibited an aggressive clinical course with rapid dissemination to the spine and death shortly after the diagnosis. No significant correlation in the expression of PAX5 and TTF-1 ( = 0.43; p = 0.18) was observed. ISL-1 is widely expressed in tumors with neuroendocrine differentiation and therefore of limited value in their differential diagnosis. TTF-1 positivity does not exclude the diagnosis of primary ONB, although usually only a small percentage of cells are positive. PAX5 expression is infrequent (27.27%) in ONB; however, if present it can be associated with a very aggressive clinical course.


Sujet(s)
Protéines de liaison à l'ADN/biosynthèse , Esthésioneuroblastome olfactif/métabolisme , Protéines à homéodomaine LIM/biosynthèse , Tumeurs du nez/métabolisme , Protéine activatrice spécifique des lymphocytes B/biosynthèse , Facteurs de transcription/biosynthèse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques tumoraux/analyse , Protéines de liaison à l'ADN/analyse , Esthésioneuroblastome olfactif/anatomopathologie , Femelle , Humains , Immunohistochimie , Protéines à homéodomaine LIM/analyse , Mâle , Adulte d'âge moyen , Fosse nasale/anatomopathologie , Tumeurs du nez/anatomopathologie , Protéine activatrice spécifique des lymphocytes B/analyse , Facteurs de transcription/analyse , Jeune adulte
11.
Pol J Pathol ; 67(1): 39-45, 2016 Mar.
Article de Anglais | MEDLINE | ID: mdl-27179273

RÉSUMÉ

Metastatic tumors involving salivary glands arising from the non-head and neck area are very rare. Renal cell carcinoma (RCC) is known for its high propensity for metastasis to unusual localizations. RCC metastasis to the maxillofacial area is an uncommon event (16%), but metastasis to salivary glands is extremely rare. We report a series of 9 such cases retrieved from two institutions. The group included 6 females and 3 males. The age at diagnosis ranged from 60 to 97 years (mean 72.6 years). The tumors involved the parotid gland in 7 cases, and the submandibular and small salivary gland of the oral cavity in 1 case each. The size of tumors ranged from 0.4 to 5 cm. Total parotidectomy with selective neck dissection was performed in 4 cases, while superficial parotidectomy was performed in 1 case and simple resection in 3 cases. Histologically, all the tumors were clear cell renal cell carcinomas, and therefore the differential diagnosis mainly included clear cell variants of salivary gland carcinomas. The parotid gland was the initial manifestation of renal malignancy in 4 of the cases, while in the remaining 5 cases a history of RCC had been known. The salivary gland involvement developed from 11 months to 13 years after the time of diagnosis of the primary tumor. In 2 cases it was the first site of dissemination. Pathologists need to maintain a high index of suspicion for the possibility of metastasis when confronted with oncocytic or clear cell neoplasms developing in salivary glands. RCC, although rare, should be included in this differential diagnosis.


Sujet(s)
Néphrocarcinome/secondaire , Tumeurs du rein/anatomopathologie , Tumeurs des glandes salivaires/secondaire , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen
12.
Pol J Pathol ; 67(1): 84-90, 2016 Mar.
Article de Anglais | MEDLINE | ID: mdl-27179279

RÉSUMÉ

Cribriform adenocarcinoma of the tongue and minor salivary glands (CAMSG) was first described 16 years ago. It typically presents as a mass at the base of the tongue with early spread to lymph nodes, but without potential for distant metastases. In the 2005 World Health Organization Classification of Tumors the entity was classified as a possible variant of polymorphous low-grade adenocarcinoma (PLGA). Since then, more than 40 cases have been described in the English literature. Recently, PRKD1-3 translocation was found in more than 80% of CAMSGs. In some of those cases ARID1A or DDX3X was the translocation partner. We reviewed 183 primary carcinomas of major and minor salivary glands, resected at the Medical University of Gdansk, Poland, in the period 1992-2012, and identified only one case of CAMSG. A giant tumor developed at the base of the tongue in a 76-year-old man. The primary tumor was resected with multiple bilateral cervical lymph node metastases. The patient received radiotherapy but died 10 months after the surgery due to causes not related to the primary cancer. The tumor presented PRKD3 rearrangement as confirmed by FISH. As the tumor is extremely rare (it represented only 0.5% of salivary gland tumors in our series), the controversy on its nosological status is still unresolved. This is the first report in the world literature of a patient who died in the course of CAMSG.


Sujet(s)
Adénocarcinome/génétique , Protéine kinase C/génétique , Tumeurs de la langue/génétique , Adénocarcinome/anatomopathologie , Sujet âgé , Humains , Hybridation fluorescente in situ , Mâle , Fumer/épidémiologie , Tumeurs de la langue/anatomopathologie
13.
Vet Comp Oncol ; 14(3): e70-82, 2016 Sep.
Article de Anglais | MEDLINE | ID: mdl-25041470

RÉSUMÉ

Olfactory neuroblastoma (ONB) is a rare tumour of nasal cavity and paranasal sinuses that arises from the olfactory neuroepithelium and has unpredictable clinical course. As the sense of smell is phylogenetically one of the first senses and olfactory neuroepithelium is evolutionary conserved with striking similarities among different species, we performed an extensive analysis of the literature in order to evaluate the similarities and differences between animals and humans on the clinical, morphological, immunohistochemical, ultrastructural and molecular level. Our analysis revealed that ONB was reported mainly in mammals and showed striking similarities to human ONB. These observations provide rationale for introduction of therapy modalities used in humans into the veterinary medicine. Animal models of neuroblastoma should be considered for the preclinical studies evaluating novel therapies for ONB.


Sujet(s)
Esthésioneuroblastome olfactif/médecine vétérinaire , Fosse nasale/anatomopathologie , Tumeurs du nez/médecine vétérinaire , Animaux , Esthésioneuroblastome olfactif/anatomopathologie , Humains , Tumeurs du nez/anatomopathologie
14.
J Ethnopharmacol ; 176: 413-23, 2015 Dec 24.
Article de Anglais | MEDLINE | ID: mdl-26549269

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Grasshopper, belonging to Chorthippus sp., is a widespread insect inhabiting Polish territory. According to folk knowledge and folk tales, the grasshopper abdominal secretion was used by villagers of Central and South-West Poland as a natural drug accelerating the wound healing process. AIM OF THE STUDY: In the reported study the hypothesis about beneficial properties of grasshopper abdominal secretion on hard to heal wounds was verified. MATERIALS AND METHODS: The study was carried out with the use of a murine model (mice C57BL/6). In order to verify the beneficial properties of grasshopper abdominal secretion, the wounds of 8mm in diameter were formed on one side of each tested mouse. The influence of ethanolic extract of insects' secretion on healing process was evaluated in comparison to ethanolic solution of allantoin and 30% aqueous solution of ethanol (medium). The observation was carried out over a 14 day period. Finally the statistical analysis (ANOVA) was carried out to highlight the differences in wound healing rate between applied preparations. Moreover, qualitative composition of grasshoppers' secretion was studied with the use of GC/MS technique. RESULTS: During the first three days of observation, wounds treated with allantoin were healed with higher efficiency in comparison to ethanol and insect secretion preparations. The trend of healing changed from the 4th day of observation. Wounds treated with grasshoppers' abdominal secretion were closuring faster than wounds treated with allantoin or ethanol. In this part of observation, in the case of allantoin and ethanol application, the wound healing efficiency was similar. Since the 9th day of experiment the measurement of wounds size was problematic, due to crust formation. Finally at the 14th day of the study, wounds were totally healed. Morphological study enabled to observe all the phases of healing. In the 5th and 8th day, the infiltration of neutrophils and mononuclear cells in dermis was observed, which is characteristic for inflammatory phase of wound healing. On the 8th day of experiments, granulation of the tissue was clearly observed in the tested groups. Reepithelialization phase was observed from the 5th to 14th day, when the wound was totally healed. The analytical approach enabled to identify 38 compounds of hydrophobic or hydrophilic character. Among them, 6 amino acids, 14 organic acids and their derivatives, one sterol, 4 hydrocarbons, 5 carbohydrates, 2 inorganic acids, 4 alcohols, one diamine and one nucleoside were identified. CONCLUSION: The obtained results enabled to recognize the composition of grasshopper abdominal secretion. Some of the identified compounds possess therapeutic properties described in the literature. The performed in vivo study proved that application of insects secretion accelerates the healing process. The obtained results positively verified the scientific hypothesis based on ethnopharmacological premises about the beneficial properties of grasshopper abdominal secretion on wound healing process.


Sujet(s)
Abdomen , Sécrétions corporelles , Sauterelles , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Allantoïne/composition chimique , Animaux , Sécrétions corporelles/composition chimique , Éthanol/composition chimique , Femelle , Chromatographie gazeuse-spectrométrie de masse , Souris de lignée C57BL , Modèles animaux , Peau/traumatismes , Peau/anatomopathologie
15.
Transplant Proc ; 46(8): 2903-7, 2014 Oct.
Article de Anglais | MEDLINE | ID: mdl-25380947

RÉSUMÉ

BACKGROUND: Sebaceous carcinoma (SC) is a very rare and aggressive malignant skin cancer that appears to occur with a greater frequency in the clinical setting of chronic immunosuppression; however, it is not reported in the literature as frequently as is squamous cell carcinoma (SCC). We report 2 cases of SC in organ transplant patients from clinical and histopathological points of view. METHODS: A 48-year-old patient after 3 renal transplantations (1986, 1986, and 1998) was presented to the Dermatology Department in 1999 because of a papillomatous lesion along her right upper eyelid. The lesion was excised. Histopathologically, it was diagnosed as a SC. There was no lymphovascular invasion and no metastasis; therefore no other treatment was included. No symptoms of recurrent disease were present 14 years since diagnosis. An 87-year-old patient after a renal transplantation in 1989 was referred to dermatologist in 1993 because of the lesion on his right temple. The lesion was excised; histopathologically, it was diagnosed as SC. Because of metastatic disease, he had a course of radiotherapy to the right side of the neck. The immunosuppressive drugs azathioprine and cyclosporine A were reduced. The patient died of metastatic disease 1 year later (3 years since diagnosis). Both patients had very high cumulative UV exposition during their lifetimes, and many skin cancers were diagnosed, especially SCC. RESULTS: It is necessary to realize that this cancer occurs more frequently in organ transplant patients, and its correct diagnosis is an essential issue because it has significantly more aggressive behavior than does SCC. In the 2 presented patients, we observed very rapid progression of disease. Despite aggressive treatment and reduction of immunosuppressive drugs, the second patient died 3 years after diagnosis. CONCLUSIONS: Regular dermatological follow-up is required in the population of organ transplant patients to identify all skin tumors in the early stage.


Sujet(s)
Sujet immunodéprimé , Immunosuppression thérapeutique , Immunosuppresseurs/administration et posologie , Transplantation rénale , Sujet âgé de 80 ans ou plus , Azathioprine/administration et posologie , Carcinome épidermoïde/épidémiologie , Ciclosporine/administration et posologie , Issue fatale , Femelle , Humains , Immunosuppression thérapeutique/effets indésirables , Mâle , Adulte d'âge moyen , Tumeurs primitives multiples/épidémiologie , Tumeurs des glandes sébacées/épidémiologie , Tumeurs des glandes sébacées/immunologie , Tumeurs des glandes sébacées/anatomopathologie , Tumeurs cutanées
16.
Br J Cancer ; 110(4): 991-1000, 2014 Feb 18.
Article de Anglais | MEDLINE | ID: mdl-24448358

RÉSUMÉ

BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients develop distant metastases following pulmonary resection. Currently, there are no reliable factors allowing for individual selection of high-risk patients for adjuvant systemic therapies. METHODS: We assessed by quantitative reverse transcription PCR microRNA (miRNA) expression in 273 stage I-IIIA NSCLC samples. Expression of 677 miRNAs was evaluated in fresh-frozen tumour samples in the training cohort of 50 squamous cell carcinoma (SCC) patients who underwent curative surgery. Of those, 20 patients developed distant metastases, and 30 were free of recurrence for >4 years. In the second step, miRNAs with highest predictive value for distant relapse were re-evaluated in formalin-fixed paraffin-embedded material in an independent group of 134 stage I-IIIA SCC patients. Additionally, the same miRNAs were investigated in 89 lung adenocarcinoma (AC) patients and in normal lung parenchyma (NLP). RESULTS: In the training cohort of SCC, six miRNAs were differently expressed in the non-recurrent vs recurrent groups and correlated with distant recurrence-free survival, however none reached the level of significance after correction for multiple testing. Of these six miRNAs, miR-662, -192 and -192* were confirmed as prognostic in the independent SCC cohort. Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC. CONCLUSIONS: We identified three new miRNAs predictive of distant relapse in operable SCC. Future miRNA studies should account for differences between NSCLC subtypes.


Sujet(s)
Adénocarcinome/génétique , Carcinome pulmonaire non à petites cellules/génétique , Carcinome épidermoïde/génétique , Tumeurs du poumon/génétique , microARN/génétique , Adénocarcinome/anatomopathologie , Adénocarcinome pulmonaire , Adulte , Sujet âgé , Marqueurs biologiques tumoraux/génétique , Carcinome pulmonaire non à petites cellules/anatomopathologie , Carcinome pulmonaire non à petites cellules/chirurgie , Carcinome épidermoïde/anatomopathologie , Carcinome épidermoïde/chirurgie , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Poumon/anatomopathologie , Tumeurs du poumon/anatomopathologie , Mâle , microARN/biosynthèse , Adulte d'âge moyen , Métastase tumorale , Récidive tumorale locale/génétique , Récidive tumorale locale/anatomopathologie , Pronostic , Jeune adulte
17.
Br J Cancer ; 107(5): 793-9, 2012 Aug 21.
Article de Anglais | MEDLINE | ID: mdl-22850551

RÉSUMÉ

BACKGROUND: To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC). METHODS: We analysed 130 HER2-positive MBC treated with trastuzumab-based therapy. MET and HGF gene copy numbers (GCN) were assessed by fluorescence in situ hybridisation (FISH) in primary breast cancer samples. Receiver operating characteristic analysis was applied to find the best cutoff point for both MET and HGF GCN. RESULTS: MET FISH-positive cases (N=36, mean 3.72) had a significantly higher trastuzumab failure rate (44.4% vs 16.0%; P=0.001) and a significantly shorter time to progression (5.7 vs 9.9 months; HR 1.74; P=0.006) than MET FISH-negative cases (N=94, mean <3.72). Hepatocyte growth factor GCN was evaluated in 84 cases (64.6%). Receiver operating characteristic analysis identified 33 HGF FISH-positive patients (mean HGF GCN 3.01). HGF FISH-positive status was significantly associated with higher risk of failure (30.3% vs 7.8%; P=0.007) as compared with HGF FISH-negative cases (N=51, mean <3.01). MET and HGF FISH-positive status was highly correlated (P<0.001) and combination of both biomarkers did not increase predictive value of either considered separately. CONCLUSION: High GCNs of MET and HGF associate with an increased risk of trastuzumab-based therapy failure in HER2-positive MBC.


Sujet(s)
Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/génétique , Dosage génique , Facteur de croissance des hépatocytes/génétique , Protéines proto-oncogènes c-met/génétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Anticorps monoclonaux humanisés/administration et posologie , Antinéoplasiques/administration et posologie , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Résistance aux médicaments antinéoplasiques , Femelle , Facteur de croissance des hépatocytes/métabolisme , Humains , Immunohistochimie , Hybridation fluorescente in situ , Adulte d'âge moyen , Pronostic , Protéines proto-oncogènes c-met/métabolisme , Récepteur ErbB-2/biosynthèse , Récepteur ErbB-2/métabolisme , Études rétrospectives , Trastuzumab
18.
J Eur Acad Dermatol Venereol ; 26(12): 1565-71, 2012 Dec.
Article de Anglais | MEDLINE | ID: mdl-22092511

RÉSUMÉ

BACKGROUND: Diffuse cutaneous mastocytosis (DCM) is an extremely rare disease characterized by mast cell (MCs) infiltration of the entire skin. Little is known about the natural course of DCM. OBJECTIVES: We decided to characterize clinical manifestations, the frequency of MCs mediator-related symptoms and anaphylaxis, risk of systemic mastocytosis (SM) and prognosis, based on 10 cases of DCM, the largest series published to date. METHODS: Diffuse cutaneous mastocytosis, DCM was confirmed by histopathological examination of skin samples in all cases. SCORing Mastocytosis (SCORMA) Index was used to assess the intensity of DCM. The analysis of clinical symptoms and laboratory tests, including serum tryptase levels was performed. Bone marrow biopsy was done only in selected cases. RESULTS: Large haemorrhagic bullous variant of DCM (five cases) and infiltrative small vesicular variant (five cases) were identified. The skin symptoms appeared in age-dependent manner; blistering predominated in infancy, whereas grain-leather appearance of the skin and pseudoxanthomatous presentation developed with time. SM was not recognized in any of the patients. Mast cell mediator-related symptoms were present in all cases. Anaphylactic shock occurred in three patients. Follow-up performed in seven cases revealed slight improvement of skin symptoms, reflected by decrease of SCORMA Index in all of them. Serum tryptase levels declined with time in six cases. CONCLUSIONS: Diffuse cutaneous mastocytosis, DCM is a heterogeneous, severe, cutaneous disease, associated with mediator-related symptoms and risk of anaphylactic shock. Although our results suggest generally favourable prognosis, the review of the literature indicate that SM may occur. Therefore, more guarded prognosis should be given in DCM patients.


Sujet(s)
Mastocytose cutanée/diagnostic , Adulte , Enfant , Femelle , Humains , Nourrisson , Nouveau-né , Mâle , Mastocytose cutanée/anatomopathologie
19.
Histopathology ; 49(3): 248-55, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16918971

RÉSUMÉ

AIMS: To assess the expression of cytokeratin (CK) 5/6 in bilateral breast cancers and to assess the relationship between its expression and other prognostic variables, as well as between CK5/6 expression and patients' survival. METHODS AND RESULTS: The expression of CK5/6, PTEN protein, oestrogen receptor, progesterone receptor, p53 and c-erbB-2 protein were evaluated by immunohistochemistry in 88 primary breast cancers diagnosed in 44 women. To assess the prognostic value of studied factors, Cox regression analysis was performed. Expression of CK5/6 was found in 23 of 88 primary breast carcinomas (23/88; 26%). The hazard ratio of development of distant metastasis in patients in whom at least one cancer was CK5/6+ was 99.8 (P=0.037) and in patients with at least one carcinoma with reduced PTEN expression it was 10.8 (P=0.044). CK5/6 expression was correlated with absence of oestrogen (P<0.0001) and progesterone receptors (P<0.0001) and very strong expression of p53 (P<0.05). Reduced PTEN expression was correlated with presence of axillary metastases (P<0.01), with very strong expression of c-erbB-2 (P<0.05) and with reduced expression of oestrogen receptor (P<0.05). CONCLUSIONS: Analysis of expression of CK5/6 and PTEN protein in bilateral breast carcinomas may be of value in clinical practice and warrant further studies.


Sujet(s)
Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Kératines/biosynthèse , Tumeurs primitives multiples/métabolisme , Tumeurs primitives multiples/anatomopathologie , Phosphohydrolase PTEN/biosynthèse , Marqueurs biologiques tumoraux/analyse , Tumeurs du sein/mortalité , Femelle , Gènes erbB-2 , Humains , Immunohistochimie , Métastase lymphatique/anatomopathologie , Tumeurs primitives multiples/mortalité , Pronostic , Récepteurs des oestrogènes/métabolisme , Récepteurs à la progestérone/métabolisme , Analyse de survie , Taux de survie , Protéine p53 suppresseur de tumeur
20.
Br J Dermatol ; 147(4): 775-80, 2002 Oct.
Article de Anglais | MEDLINE | ID: mdl-12366429

RÉSUMÉ

Cutaneous presentation of B-cell chronic lymphocytic leukaemia (B-CLL) is uncommon, and the influence of skin changes on B-CLL prognosis is unclear. We report a patient with B-CLL Rai II, with multiple nodular skin infiltrations on the trunk, upper arms and thighs as well as constitutional symptoms, who was successfully treated with cladribine. The peripheral blood (PB) lymphocytes were CD19, CD20, CD23 and CD5 positive, which confirmed the diagnosis of B-CLL. Skin biopsy of one of the lesions showed an intense infiltrate composed of small lymphocytes with no epidermotropism. These cells also showed the expression of CD19, CD20, CD23 and CD5 antigens similar to those presented on PB lymphocytes. Polymerase chain reaction performed on bone marrow lymphocytes and a lesional skin biopsy using consensus primers for immunoglobulin heavy-chain genes also showed the same monoclonal population of B lymphocytes both in the bone marrow and in the skin. The patient received four courses of cladribine 0.12 mg kg-1 daily as a 2-h infusion for five consecutive days. The courses were repeated at monthly intervals. The lymphocytosis gradually decreased and the PB count normalized after three courses. At the same time, a significant decrease in the cutaneous symptoms was observed. The patient became free of skin tumours after the fourth course of cladribine; only slight discoloration at the previous sites of cutaneous infiltration remained. There was no relapse of leukaemia cutis during a further 7 months of observation.


Sujet(s)
Antinéoplasiques/usage thérapeutique , Chloro-2 désoxyadénosine/usage thérapeutique , Leucémie chronique lymphocytaire à cellules B/traitement médicamenteux , Infiltration leucémique/traitement médicamenteux , Peau/anatomopathologie , Sujet âgé , Humains , Leucémie chronique lymphocytaire à cellules B/diagnostic , Leucémie chronique lymphocytaire à cellules B/anatomopathologie , Mâle
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...